Maat Pharma · EURONEXT:MAAT
Maat Pharma — Investor Presentation (October 2025)
31 slides from Maat Pharma's investor presentation, October 2025
Slide 1: Boosting Survival Through Innovative Immune Modulation
Boosting Survival Through Innovative Immune Modulation October 2025
Slide 2: Disclaimer
MaaT Pharma September 2025 2 Disclaimer This document has been prepared by MaaT Pharma (the "Company") The information contained in this document has not been subject to This document contains certain forward-looking statements. These and is for information and background purposes only. independent
Slide 3: Company Overview
Company Overview
Slide 4: MaaT013 (Xervyteg) in aGvHD: Achieved Primary Endpoint of Phase 3 Study
MaaT Pharma September 2025 4 MaaT013 (Xervyteg®) in aGvHD: Achieved Primary Endpoint of Phase 3 Study Registration in Europe Will Spearhead Microbiome Therapies in Oncology Xervyteg® Moving Closer to Multi-assets platform Financial Commercial Launch focused on oncology Overview Positive Pivotal Phas
Slide 5: Leveraging Microbiome Modulation in Oncology: Mechanisms for Enhanced Survival Outcomes
MaaT Pharma September 2025 5 Leveraging Microbiome Modulation in Oncology: Mechanisms for Enhanced Survival Outcomes in Multiple Settings Expected benefits Xervyteg® and production of functional metabolites Control of inflammation and restoration of gut Restoration of microbiota diversity Resolution
Slide 6: Oncology-Focused Platform Fueling a Deep Pipeline of Drug Candidates
MaaT Pharma September 2025 6 Oncology-Focused Platform Fueling a Deep Pipeline of Drug Candidates Native Ecosystem Co-cultured Ecosystem Integrated Production Driving near-term value Progressing next-generation Leading capabilities in full ecosystem with the donor-derived MET-N platform co-cultured
Slide 7: A Strong Pipeline With Multiple Value Inflection Milestones and a Close-to-Market Asset
MaaT Pharma September 2025 7 A Strong Pipeline With Multiple Value Inflection Milestones and a Close-to-Market Asset Recent or Upcoming Program Indication Market potential Preclinical Phase 1 Phase 2 Phase 3 MAA Status milestones Primary EU MAA currently ARES Xervyteg® 1L : 10k patients2 endpoint me
Slide 8: Xervyteg in aGvHD
Xervyteg® in aGvHD
Slide 9: Understanding and Addressing Acute Graft-versus-Host Disease (aGvHD)
Xervyteg ® • aGvHD → Salvage → Salvage ODD ODD EMA/FDA MaaTEMA/FDA Pharma Quick action → Quick → action September 2025 9 Understanding and Addressing Acute Graft-versus-Host Disease (aGvHD) Donor immune cells recognize the recipient’s tissues as Treatment Paradigm foreign, leading to an immune-media
Slide 10: Xervyteg: A Standardised, Pooled, Allogeneic Microbiota Medicine Under Review by the EMA
Xervyteg ® • aGvHD → Salvage → Salvage ODD ODD EMA/FDA MaaTEMA/FDA Pharma Quick action → Quick → action September 2025 10 Xervyteg®: A Standardised, Pooled, Allogeneic Microbiota Medicine Currently Under Review by the EMA Full ecosystem High-diversity (including richness) Characteristics: 01 L
Slide 11: ARES: a Pivotal Phase 3 Trial Exploring Xervyteg in Third-Line aGvHD
Xervyteg ® • aGvHD → Salvage → Salvage ODD ODD EMA/FDA MaaTEMA/FDA Pharma → Quick action → Quick action September 2025 11 ARES: a Pivotal Phase 3 Trial Exploring Xervyteg® in Third-Line aGvHD Following Steroid and Ruxolitinib Failure Milestones: Topline results announced January 8th 2025 I EMA MAA f
Slide 12: ARES: Strong Response to Xervyteg in aGvHD Following Steroid and Ruxolitinib Failure
Xervyteg ® • aGvHD → Salvage ODD EMA/FDA MaaT Pharma → Quick action September 2025 12 ARES: Strong Response to Xervyteg® in aGvHD Following Steroid and Ruxolitinib Failure D28 Response Rate (%) Topline Results “ These outcomes underscore the curative role of microbiota- 80 80 based therapies in achi
Slide 13: ARES: Unprecedented Probability of Survival Compared to Historical Data
Xervyteg ® • aGvHD → Salvage ODD EMA/FDA MaaT Pharma → Quick action September 2025 13 ARES: Unprecedented Probability of Survival Compared to Historical Data with Best Available Therapy (BAT) Overall Survival, ARES vs BAT Probability of Survival by D28 Response Probability of Survival (%) Probabilit
Slide 14: Xervyteg, a potential triple first
Key Takeaways Xervyteg®, a potential triple first • 1st Microbiota Therapy in Europe (submission) • 1st Microbiota Therapy in Oncology Worldwide • 1st Treatment for Third- line GI-aGvHD
Slide 15: MaaT033 in allo-HSCT
MaaT033 in allo-HSCT
Slide 16: Phoebus: MaaT033 Phase 2b RCT Adjunctive Treatment for Allo-HSCT Patients
MaaT033 • Allo-HSCT → Ambulatory ODD EMA MaaT Pharma → Adjunctive September 2025 16 Phoebus: MaaT033 Phase 2b RCT Potential Adjunctive Treatment for Patients Receiving Allo-HSCT Visit 1 Visit 2 15 – 21 days Visit 3 Visit 6 Visit 10 D-21 D-7 D-0 Neutrophil recovery D+21 M+3 M+12 Pre Allo-HSCT Post Al
Slide 17: Commercial And Distribution Strategy in Hemato-Oncology
Commercial And Distribution Strategy in Hemato- Oncology
Slide 18: Leadership in Hemato-Oncology Across the Full Care Continuum of HSCT
MaaT Pharma September 2025 18 Leadership in Hemato-Oncology Across the Full Care Continuum of HSCT Unique Value Proposition A Significant Market Opportunity Unique immunosuppressant-sparing, microbiome-based treatment option in aGvHD Well defined target population for both products Prescribers are c
Slide 19: Licensing Late Stage Asset Xervyteg to Clinigen for Commercialization in Europe
MaaT Pharma September 2025 19 Licensing Late Stage Asset Xervyteg® to Clinigen for Commercialization in Europe • Leading position in hospital distribution • Recognized expertise in critical care ~75-€100m • Hemato-Oncology Portfolio in Europe • Extanded network of prescribers • Specialist in Early A
Slide 20: Synergy with Purpose: Growth Driven by Patient-Centric Collaboration
MaaT Pharma September 2025 20 Synergy with Purpose: Growth Driven by Patient-Centric Collaboration Commercialization MaaT Pharma will manufacture and supply the product to Clinigen. Scope of the Collaboration If approved, MaaT Pharma to hold the Marketing Authorization. EU27 + Iceland, Norway, Liech
Slide 21: Bringing Xervyteg to Market: Financial terms of the Commercial Partnership
MaaT Pharma September 2025 21 Bringing Xervyteg® to Market: Financial terms of the Commercial Partnership for Europe Financial Terms Upfront payment Regulatory & Sales milestones Royalties on net sales Drug Supply 10.5M€ 18M€ Mid-thirties Set Cost Terms European Market for Xervyteg® Total Adressable
Slide 22: Early Access Program in Europe will Transition to Clinigen
MaaT Pharma September 2025 22 Early Access Program in Europe will Transition to Clinigen Supplying The Increasing International Demand Clinical Outcome Number of patients 140 • 252 requests and 173 GvHD patients analyzed as of 120 October 2024 and presented at EHA 2025: 100 +75% • Efficacy (All line
Slide 23: Largest European cGMP Manufacturing Facility for Microbiome Ecosystem Therapies
→ cGMP → Scalable MaaT Pharma Largest European cGMP Manufacturing Facility for Microbiome Ecosystem TherapiesTM Xervyteg® 9,000 3,000 Leading microbiome therapies fully integrated manufacturing MaaT033 1,300,000 6,000 and development platform: streamlined product development, scaleup and GMP process
Slide 24: Future Growth Drivers in Immuno-Oncology
Future Growth Drivers in Immuno- Oncology
Slide 25: Unlocking the Potential of Checkpoint Inhibitors
→ ICI MaaT034 MaaT034••IO IO–-Solid Melanoma Tumors MaaT Pharma → Combo September 2025 25 Unlocking the Potential of Checkpoint Inhibitors: How Full-Ecosystem Gut Microbiome Overcomes Primary Resistance Immune Checkpoint Inhibitors (ICI) significantly Leveraging full ecosystem microbiome improve out
Slide 26: From Proof to Platform: An Integrated IO Strategy
MaaT Pharma September 2025 26 From Proof to Platform: An Integrated IO Strategy Coordinated development path leveraging on proven safety profile of Xervyteg® while optimizing MaaT034 2 MET-N MET-C 1 Xervyteg® MaaT033 MaaT03X Full High Diversity Enhancement/ Microbiome-based Rationally Selected Targe
Slide 27: Looking Ahead & Key Takeaways
Looking Ahead & Key Takeaways
Slide 28: Several Major Near-Term Value Inflection Expected Milestones
MaaT Pharma September 2025 28 Several Major Near-Term Value Inflection Expected Milestones 2025 2026 2027 Partnered Xervyteg® I GvHD Xervyteg® Ares Ph3 28 days GI-ORR results Jan 25 GvHD | MA approval EMA H2 26 MA application EMA June 25 Hemato Ares Ph3 OS results H2 25 Xervyteg® GvHD | Potential pi
Slide 29: Key takeaways on MaaT Pharma
MaaT Pharma September 2025 29 Key takeaways on MaaT Pharma Progress of the Pipeline Leadership in Hemato-Oncology through immune modulation with microbiome-derived therapies across all treatment stages Exploring Immuno-Oncology preclinically with MaaT034 with strong anti-tumor activity coupled with
Slide 30: Corporate Social Responsibility
MaaT Pharma September 2025 30 Corporate Social Responsibility MaaT Pharma is a leading, late-stage clinical Patients are the priority. MaaT Pharma is committed → Innovate and raise awareness to deliver company committed to advancing gut microbiome to patients and to the protection of human health by
Slide 31: Thank you
Thank you